Compare IONQ Inc (IONQ) vs Mesoblast Limited (MESO) Price & Performance

IONQ trades at $44.82, up 5.38% with a bullish technical signal supported by moving averages. The quantum computing company reported explosive 287% revenue growth in Q2 2026 to $80.1 million and raised its full-year outlook, though it remains deeply unprofitable with a -553% net margin. Recent catalysts include a $28 million DARPA contract extension and strong analyst sentiment with a $73.33 consensus price target representing 64% upside potential.

While IONQ demonstrates exceptional revenue momentum and technological leadership in quantum computing, investors face substantial risk from persistent losses, high cash burn, and valuation multiples exceeding 60x sales. The stock offers significant growth potential but requires tolerance for volatility and a long-term horizon given the nascent stage of quantum commercialization.

MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.

MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.